New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDSIP vs Orforglipron

DSIP vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Sleep OptimizationCognitive Enhancement
DSIP
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
~30–60 minutes; however downstream sleep effects last 4–6 hours
~12 hours (once-daily oral dosing)
Admin Route
SubQ, IV, Intranasal
Oral
Research
Typical Dose
100–400 mcg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once nightly
Once daily
Key Benefits
  • Induces and deepens delta-wave (slow-wave) sleep
  • Reduces cortisol and normalizes HPA axis
  • Improves sleep quality in insomnia patients
  • Anti-stress and anxiolytic effects
  • May improve opiate/alcohol withdrawal symptoms
  • Analgesic properties through opioid modulation
  • Antioxidant and neuroprotective effects
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Generally well tolerated
  • Mild grogginess next morning at higher doses
  • Rare: hypotension
  • Potential for altered dream patterns
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With